Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial

BACKGROUND: Hepatocellular carcinoma (HCC) accounts for 75–85% of primary liver cancers and is prevalent in the Asia-Pacific region. Till now, trans-arterial chemoembolization (TACE) is still one of common modalities in managing unresectable intermediate-stage HCC. However, post-TACE residual viable...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liang-Cheng, Chiou, Wen-Yen, Lin, Hon-Yi, Lee, Moon-Sing, Lo, Yuan-Chen, Huang, Li-Wen, Chang, Chun-Ming, Hung, Tsung-Hsing, Lin, Chih-Wen, Tseng, Kuo-Chih, Liu, Dai-Wei, Hsu, Feng-Chun, Hung, Shih-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437913/
https://www.ncbi.nlm.nih.gov/pubmed/30922261
http://dx.doi.org/10.1186/s12885-019-5461-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437913/
https://www.ncbi.nlm.nih.gov/pubmed/30922261
http://dx.doi.org/10.1186/s12885-019-5461-3

Ejemplares similares